These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15662237)

  • 61. Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation.
    Omboni S; Parati G; Palatini P; Vanasia A; Muiesan ML; Cuspidi C; Mancia G
    J Hypertens; 1998 Jun; 16(6):733-8. PubMed ID: 9663912
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of diastolic dysfunction in hypertensive left ventricular hypertrophy.
    Bella JN
    Am J Hypertens; 2006 Sep; 19(9):937-8. PubMed ID: 16942936
    [No Abstract]   [Full Text] [Related]  

  • 63. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension.
    Black HR; Elliott WJ; Weber MA; Frishman WH; Strom JA; Liebson PR; Hwang CT; Ruff DA; Montoro R; DeQuattro V; Zhang D; Schleman MM; Klibaner MI
    Hypertension; 2001 Nov; 38(5):1118-23. PubMed ID: 11711508
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy.
    Islim IF; Watson RD; Ihenacho HN; Ebanks M; Singh SP
    Cardiology; 2001; 96 Suppl 1():10-8. PubMed ID: 11574741
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
    Rakić D; Rumboldt Z; Bagatin J; Polić S
    Croat Med J; 2002 Dec; 43(6):672-9. PubMed ID: 12476475
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of amlodipine on echocardiographic variables in cats with systemic hypertension.
    Snyder PS; Sadek D; Jones GL
    J Vet Intern Med; 2001; 15(1):52-6. PubMed ID: 11215913
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
    Yasunari K; Maeda K; Watanabe T; Nakamura M; Yoshikawa J; Asada A
    J Am Coll Cardiol; 2004 Jun; 43(11):2116-23. PubMed ID: 15172423
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessment of preclinical target organ damage in hypertension: left ventricular hypertrophy.
    Rosei EA
    J Hypertens; 2001 Dec; 19(12):2288-90. PubMed ID: 11725178
    [No Abstract]   [Full Text] [Related]  

  • 70. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects.
    Verdecchia P; Angeli F; Gattobigio R; Sardone M; Pede S; Reboldi GP
    Am J Hypertens; 2006 May; 19(5):493-9. PubMed ID: 16647622
    [TBL] [Abstract][Full Text] [Related]  

  • 71. How reliable are serial echocardiographic measurements in detecting regression in left ventricular hypertrophy and changes in function?
    Gardin JM
    J Am Coll Cardiol; 1999 Nov; 34(5):1633-6. PubMed ID: 10551716
    [No Abstract]   [Full Text] [Related]  

  • 72. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
    Wachtell K; Palmieri V; Olsen MH; Gerdts E; Papademetriou V; Nieminen MS; Smith G; Dahlöf B; Aurigemma GP; Devereux RB
    Circulation; 2002 Jul; 106(2):227-32. PubMed ID: 12105163
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pulse pressure is the best predictor of future left ventricular mass and change in left ventricular mass: 10 years of follow-up.
    Jokiniitty JM; Majahalme SK; Kähönen MA; Tuomisto MT; Turjanmaa VM
    J Hypertens; 2001 Nov; 19(11):2047-54. PubMed ID: 11677371
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Regression of left ventricular hypertrophy in hypertension--does it reduce cardiovascular risk?
    Braz Nogueira J
    Rev Port Cardiol; 2005; 24(7-8):1007-13. PubMed ID: 16240686
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Can echocardiography identify mildly hypertensive patients at high risk, left untreated based on current guidelines?
    Abergel E; Chatellier G; Battaglia C; Menard J
    J Hypertens; 1999 Jun; 17(6):817-24. PubMed ID: 10459880
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study.
    de Luca N; Mallion JM; O'Rourke MF; O'Brien E; Rahn KH; Trimarco B; Romero R; De Leeuw PW; Hitzenberger G; Battegay E; Duprez D; Sever P; Safar ME
    Am J Hypertens; 2004 Aug; 17(8):660-7. PubMed ID: 15323062
    [TBL] [Abstract][Full Text] [Related]  

  • 77. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Hallberg P; Lind L; Michaëlsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
    J Hypertens; 2003 Mar; 21(3):621-4. PubMed ID: 12640257
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
    Larstorp AC; Ariansen I; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Dahlöf B; Kjeldsen SE; Wachtell K
    Hypertension; 2012 Aug; 60(2):347-53. PubMed ID: 22753219
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
    Malmqvist K; Kahan T; Edner M; Bergfeldt L
    Am J Cardiol; 2002 Nov; 90(10):1107-12. PubMed ID: 12423712
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).
    Wachtell K; Palmieri V; Gerdts E; Bella JN; Aurigemma GP; Papademetriou V; Dahlöf B; Aalto T; Ibsen H; Rokkedal JE; Devereux RB
    Am J Cardiol; 2010 Oct; 106(7):999-1005. PubMed ID: 20854964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.